Trial intelligence / Profile preview

MOTION: Riociguat in PAH

NCT02191137Phase 4Completed

Sponsor
Bayer
Start
Sep 2014
Primary completion
Jul 2016
Modality
Small Molecules
Countries
2
01

Overview

A Phase 4 trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Sep 2014; status: completed.

02

Drugs

riociguat
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on NCT02191137.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02191137.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call